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1. Introduction
Progressive type of cerebral infarction (PTCI) is a cerebral infarction, which is progressive aggra-vation of neurological impairment within 6 hours 
to 1 weeks in patients with cerebral infarction, or the 
progression of the disease is still after active treatment. 
PTCI accounts for about 20% to 40% of all ischemic cere-
brovascular patients, and the morbidity and mortality are 
significantly higher than those of stable cerebral infarc-
tion, which seriously affects the prognosis of patients with 
cerebral infarction. Application of butylphthalide injection 
(Shijiazhuang Pharmaceutical Group dl-3-butylphthalide 
Pharmaceutical Co. Ltd.) combined with human serum 
albumin (Wuhan Biological Products Research Institute 
Co., Ltd.) on the treatment of PTCI in our department to 
achieve good results.
2. Data and Methods
2.1 General Information
The cases were from 120 pataients with PTCI in neurol-
ogy department of Shuyang People's Hospital of Jiangsu 
Province from January 2014 to January 2017. The general 
clinical data of the patients were age, sex, admission to 
infarct progression time, the risk factors cerebrovascular 
such as hypertension, diabetes, smoking and hyperlipid-
emia, and the blood pressure, blood glucose and blood 
lipids at admission. The patients were divided into three 
groups, there were 14 males and 16 females in group A, 
20 males and 25 females in group B, 25 males and 20 fe-
males in group C.
2.2 The Set of Standard
(1) Between the ages of 18-80; (2) the onset time is with-
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in 4.5-48 hours; (3) the diagnostic criteria of all patients 
were consistent with the standard of PTCI[1]; (4) able to 
cooperate with the NIHSS score checker; (5) understand 
and agree with this study.
The exclusion criteria include these: (1) The patients 
with arterial thrombolysis, embolectomy or fibrinolysis; 
(2) the patients with cardiac insufficiency; (3) the patients 
with severe hepatorenal insufficiency, malnutrition and 
electrolyte disturbances; (4) refusal to cooperate with the 
NIHSS score checker.
2.3 Treatment Method
All patients were immediately given aspirin enter-
ic-coated tablets 300 mg or clopidogrel hydrogen sul-
fate tablets 300 mg (aspirin enteric-coated tablets 100 
mg, qn + clopidogrel sulfate tablets 75 mg, qd were 
given the next day and later), atorvastatin calcium (40 
mg, qn), alprostadil, edaravone, ginkgo dipyridamole, 
with regulating blood sugar, blood pressure, rehabili-
tation and other conventional treatment, and the total 
course of treatment is 14 days.
Group A was included in 30 patients (14 males and 16 
females): given butylphthalide (sodium butyryl phthalate 
100 ml, intravenous drip 2 times / day for 1 week, after 
change to butyl phthalate soft capsules 0.2, 3 times/ Day 
for 21 days) + human serum albumin (5 g, intravenous 
drip, 1 times / day for 3 days) + conventional therapy; 
Group B was included in 45 patients (20 males and 25 
females): given human serum albumin (5 g, intravenous 
drip, 1 time / day for 3 days) + conventional therapy; 
Group C was included in 45 patients (25 males and 20 fe-
males): given conventional therapy.
2.4 Observation Index
The neurological deficits were scored using the National 
Institutes of Health Stroke Scale (NIHSS), the daily liv-
ing ability was assessed using the Barthel Index (BI), and 
the degree of disability and the total effective rate for 90 
days of pataints was assessed with Modified Rankin Scale 
(MRS) at the progress of cerebral infarction, 1 week, 2 
weeks, and 90 days after treatment.
2.5 Criteria of Curative Effect
According to the criteria of clinical neurological deficit 
score in patients with stroke  assessment(1995)[2]. Es-
sentially recovered: functional defect score decreased by 
46% to 90%; ignificant progress: functional defect score 
decreased by 18% to 45%; no change: functional defect 
score decreased by about 17%; deterioration: functional 
defect score decreased or increased by more than 18% or 
died. Total effective rate = (basic recovery + significant 
progress + progress) / total number of cases × 100%.
2.6 Statistical Method
SPSS24.0 statistical software was used used for statistical 
analysis of all data. The count data were represented in 
frequency or rate, and χ2 tests were used between groups; 
the measurement data were expressed by mean standard 
deviation (x + s), and the three groups were compared by 
variance analysis and after two two comparison. The dif-
ference of P < 0.05 was statistically significant.
3. Conclusion
3.1 Baseline Data of Three Groups of Patients
As shown in Table 1, there was no significant difference 
in the baseline data ( age, sex, time of admission to infarct 
progression, history of hypertension, history of diabetes 
mellitus, hyperlipidemia, smoking history and blood pres-
sure, blood glucose and blood lipids) between the three 
groups, and no statistically significant .
3.2 Comparison of the Scores Between the 1 Week 
of Treatment and the Progression of the Same 
Group
There was no significant difference in NIHSS(8.93 ± 
3.12，9.69 ± 2.88，9.51 ± 3.29）、BI(34.00 ± 24.93，
30.56 ± 19.69，33.89 ± 22.51）、mRS (3.83 ± 1.12,4.09 ± 
0.93,3.91 ± 1.14) between these after 1 week of treatment 
{NIHSS(9.50 ± 3.18, 10.02 ± 2.95, 9.51 ± 3.29); BI(31.00 
± 24.40, 28.44 ± 20.00, 32.33 ± 21.60); mRS(3.97 ± 1.10，
4.13 ± 0.94, 3.93 ±1.10)} of patients in Group A, Group 
B and Group C, indicating that the improvement of neu-
rological deficit symptoms was not obvious in the three 
groups after 1 week of treatment.
3.3 Comparison of the Scores Between the 2 
Weeks and 90 Days of Treatment and the Pro-
gression of the Same Group
The scores of NIHSS, BI and mRS of each group were 
improved, and there were significant differences (P < 0.05) 
(see Table 2), which indicated that the neurologic impair-
ment are improved after 2 weeks and 90 of treatment.
3.4 Comparison of Scores in Different Groups 
over the Same Period
After treatment for 2 weeks and 90 days, the NIHSS score 
and mRS score of group A were lower than those of group 
B and group C (P < 0.05). After 90 days of treatment, BI 
of group A was significantly higher than that of group B 
and group C (P < 0.05) (see Table 2), indicating that the 
improvement of neurological impairment in group A was 
better than that in group B and group C after 2 weeks and 
90 days of treatment.
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3.5 The Total Effective Rate of the Three Groups 
was Compared after 90 Days of Treatment
The total effective rate of group A (96.7%) > that of group 
B (88.9%) > that of group C (77.8%), there was statistical 
difference (2 = 67.601, P < 0.05) (see Table 3).
3.6 Adverse Reaction
There was no definite adverse reactions occurred in the 
three groups.
Table 1. Comparison of general baseline data between the three groups
Baseline Data Group A Group B Group C Test Value P
Age 64.93±9.03 64.47±8.41 64.71±8.01 0.028a 0.072
Sex(Male/Female) 14/16 20/25 25/20 1.211b 0.546
Admission to infarction 
progression time (hour)
27.10±6.11 24.91±7.17 24.42±6.92 1.487a 0.23
Hypertension(%) 23(76.7) 35(77.8) 37(82.2) 0.421b 0.81
Diabetes(%) 5(16.7) 13(28.9) 13(28.9)
1.754b
1.754b
0.416
0.416
Smoke(%) 9(30.0) 13(28.9) 15(33.3)
0.221b
0.221b
0.895
0.895
Hyperlipidemia(%) 13(43.3) 21(46.7) 20(44.4)
0.407b
0.221b
0.816
0.816
Systolic pressure (mmHg) 
Diastolic pressure(mmHg)
141.63±9.84
77.53±9.91
143.0±8.88
78.80±9.17
144.0±9.46
76.33±9.22
0.577a
0.736a
0.563
0.481
Blood sugar(mmol/l） 6.10±1.09 6.20±1.16 6.32±1.20 0.33a 0.718
LDL(mmol/l） 2.68±0.70 2.66±0.70 2.63±0.69 0.056a 0.945
CHOL(mmol/l） 5.16±0.50 5.23±0.54 5.16±0.54 0.228a 0.797
TG(mmol/l） 2.22±0.61 2.23±0.62 2.13±0.59 0.36a 0.699
* a is the variance analysis F value; b is chi-square test χ2 value; 1 mmHg = 0.133 kpa; LDL: low density lipoprotein; 
CHOL: total cholesterol; TG: triglyceride
Table 2. The NIHSS, BI and mRS scores were compared between the 3 groups after treatment
Group and time Number NIHSS BI mRS
Group A 30
Progress time 9.50±3.18 31.00±24.40 3.97±1.10
1 week 8.93±3.12 34.00±24.93 3.83±1.12
2 weeks 5.27±2.32*1 62.83±20.95*1 2.43±0.86*1
90 days 2.57±1.91*1 89.83±12.96*1 1.17±0.79*1
Group B 45
Progress time 10.02±2.95 28.44±20.00 4.13±0.94
1 week 9.69±2.88 30.56±19.69 4.09±0.93
2 weeks 6.76±2.60*1*2 54.56±20.58*1 2.87±0.94*1
90 days 4.22±2.34*1*2 78.56±17.57*1*2 1.82±0.94*1*2
Group C 45
Progress time 9.51±3.29 32.33±21.60 3.93±1.10
1 week 9.47±3.35 33.89±22.51 3.91±1.14
2 weeks 8.69±3.40*2 39.22±22.21*2 3.62±1.15*2
90 days 7.24±3.22*1*2 51.11±23.21*1*2 2.93±1.10*1*2
* Compared with the progress in this group,*1p < 0.05; Compare with the group A at the same time, *2p < 0.05
Table 3. The total effective rate of the 3 groups was compared after 90 days treatment
Group Total Recovered Significant progress Progress Unchanged Total effective rate χ2 p
Group A 30 6(20%) 23(76.7%) 0(0%) 1(3.3%) 96.7%
67.601 <0.05Group B 45 3(6.7) 29(64.4%) 11(24.4%) 2(4.4%) 88.9%
Group C 45 0(0%) 4(8.9%) 31(68.9%) 10(22.2%) 77.8%
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4. Conclusion
PTCI is a cerebral infarction, which is progressive ag-
gravation of neurological impairment within 6 hours to 1 
weeks in patients with cerebral infarction, or the progres-
sion of the disease is still after active treatment. According 
to the deterioration of neurological impairment in patients 
with different time, PTCI can be divided into two types, 
namely early-onset and late-onset. Davalos etc.[3] It proposed 
that the Scandinavian Stroke Scale (SSS), awareness score 
or exercise score was reduced by 2 points in 24 hours 
or a 3-point was reduced in the language score could be 
judged as early-onset PTCI, which these ratings were re-
suced in 24 hours to 1 week was classified as late-onset. 
The early-onset PCI is more common in clinical practice, 
Davalos etc.[4] It found that the deterioration of neuro-
logical function is the result of multi-factor and multiple 
mechanisms of interaction in the early stage of cerebral 
infarction. The cerebral ischemia injury excitotoxin hy-
pothesis suggests that when brain perfusion is reduced, 
glutamate and glycine transporters can be accumulated in 
the ischemic region or its surrounding area, which excites 
specific receptors as excitatory amino acids, leading to so-
dium ions and calcium ions into cells, triggering a series 
of biochemical and structural changes, for example mito-
chondrial is injured, microfilament protein is hydrolyzed, 
membrane phospholipid destruction, oxygen free radical 
formation and cell death, thereby aggravating and promot-
ing the damage of ischemic brain tissue. Its mutilation rate 
and fatality rate are very high, which seriously endangers 
human health. Thrombolytic therapy is the most effective 
treatment for acute ischemic stroke, the treatment direc-
tion is to open the occlusion of blood vessels, save the 
ischemic penumbra, PTCI super-thrombolysis window 
time, it is difficult to clear the pathogenesis in the early 
stage, and the clinical treatment is difficult, there is no 
normative clinical treatment standards, so to explore a 
good treatment strategy is particularly important.
Butylphthalide is a kind of new medicine for the treat-
ment of acute stroke in China. The experimental study 
of related animals shows that[5-10], butylphthalide is a 
multi-target anti-ischemic medicine, which can repairs 
the mitochondrial function, inhibits oxygen free radicals, 
improves the ability of antioxidant enzymes, reduces the 
infarct size, improves the degree of neurological impair-
ment, increases regional cerebral blood flow, improves 
microcirculation and energy metabolism depletion of 
cerebral ischemia, reduces the cerebral edema caused by 
cerebral ischemia and play a role in antiplatelet agglom-
eration. At present, Liying Cui etc.[11] have conducted a 
multi-center, randomized, double-blind, double-opioid 
and aspirin-controlled study of dl-3-n-butylphthalide soft 
capsules for acute ischemic stroke. The study showed that 
the curative effect of butyphthalide was better than that of 
aspirin in acute ischemia Stroke treatment on day 11 and 
day 21, which is evidence of intolerance or inability to use 
aspirin and confirms the therapeutic status of butyphtha-
lide in acute ischemic cerebrovascular disease. Therefore, 
many Chinese domestic scholars have also carried out 
the experiment of butylphthalide in the treatment of acute 
PTCI[12-15], and achieved good results.
Albumin is an important component of human plas-
ma and plays a major role in regulating plasma colloid 
osmotic pressure. Human serum albumin is mainly used 
in hypoproteinemia, ascites due to cirrhosis, burns and 
so on, by increasing the blood osmotic osmotic pressure, 
albumin can reduce the brain edema and infarct volume. 
Guohua Liang etc.[16] confirmed its efficacy and safety in 
treatment of PTCI in the study of PTCI in 130 cases, and 
found that human serum albumin can effectively reduces 
blood viscosity, thereby improving the neurological im-
pairment and the prognosishe of patients with PTCI.
This study found that the combination of butyphthalide 
and albumin in the treatment of PTCI did not show a sig-
nificant advantage after 1 week of treatment, and showed 
significant effects at 2 weeks and 90 days after treatment, 
its NIHSS and mRS were significantly lower than these of 
single albumin and conventional treatment group, and its 
BI and ADL was significantly higher than these of single 
albumin and conventional treatment group, said that the 
combination of the two drugs can be better improves the 
symptoms of neurological impairment in patients with 
PTCI, improves the prognosis, and confirms the value of 
its clinical treatment.
There was fewer samples were included in this study, 
and further expand the sample size was needed to obtain 
more reliable results to provide further evidence for the 
treatment of patients with PTCI.
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